Wall Street brokerages forecast that Nevro Corp (NYSE:NVRO) will report earnings per share (EPS) of ($0.14) for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Nevro’s earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.02). Nevro reported earnings of ($0.34) per share during the same quarter last year, which would suggest a positive year over year growth rate of 58.8%. The firm is scheduled to issue its next earnings report after the market closes on Thursday, February 22nd.
According to Zacks, analysts expect that Nevro will report full year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.32) to ($1.12). For the next financial year, analysts expect that the business will report earnings of ($0.47) per share, with EPS estimates ranging from ($0.92) to ($0.03). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Nevro.
Several research firms have weighed in on NVRO. BidaskClub lowered shares of Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a report on Monday, November 6th. ValuEngine lowered shares of Nevro from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. BMO Capital Markets restated a “buy” rating and set a $100.00 price objective on shares of Nevro in a report on Thursday, December 14th. Finally, Northland Securities restated a “buy” rating and set a $96.00 price objective on shares of Nevro in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $99.25.
Shares of Nevro (NYSE:NVRO) opened at $75.99 on Wednesday. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59. The firm has a market cap of $2,238.71, a price-to-earnings ratio of -52.41 and a beta of -0.59. Nevro has a twelve month low of $65.00 and a twelve month high of $99.63.
COPYRIGHT VIOLATION NOTICE: “Nevro Corp (NVRO) Expected to Post Earnings of -$0.14 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/nevro-corp-nvro-expected-to-post-earnings-of-0-14-per-share.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.